Chiltern International has announced the hire of Andrew Arrage as business development executive responsible for the mid-Atlantic region of the USA
Andrew Arrage has over 15 years experience in the pharmaceutical and biotech industries.
Prior to joining Chiltern, he spent over four years at BioReliance (now a subsidiary of Invitrogen) in marketing and business development for contract manufacturing.
He was a managing consultant for Pittiglio Rabin Todd and McGrath Life Sciences, implementing best practices in product development and marketing strategies for pharmaceutical and medical device clients.
He has also spent six years as a researcher for the University of Tennessee in environmental microbiology.
"Sponsors are faced with an increasingly complex and ever changing worldwide regulatory environment that can be a daunting hurdle for the globalisation of drug products and product platforms," explained Arrage.
"Chiltern provides a two-pronged solution to optimise clients' clinical development programs: a strategic approach through regulatory guidance and planning along with regionally based staff to implement and monitor global trials.
"This company is all about helping clients achieve their goals and I am looking forward to being part of that."
